[HTML][HTML] 表皮生长因子/HER2 抑制剂在非小细胞肺癌患者治疗中的作用综述
南娟， 丁燕 - Chinese Journal of Lung Cancer, 2010 - ncbi.nlm.nih.gov
… and BSC in non-small cell lung cancer patients failing erlotinib or gefitinib (LUX-LUNG 1). …
: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer. Eur …
: preliminary results of a phase 2 trial in patients with advanced non-small cell lung cancer. Eur …
[HTML][HTML] 化疗间插联合EGFR-TKIs 对比单独化疗一线治疗晚期非小细胞肺癌的meta 分析
洪超煜， 梅同华， 王进 - Chinese Journal of Lung Cancer, 2016 - ncbi.nlm.nih.gov
… alone in the first-line therapy of advanced non-small cell lung cancer (NSCLC). …
Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein …
Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein …
[PDF][PDF] 非小细胞肺癌患者EGFR‑TKI 相关间质性肺疾病发生情况的meta 分析
李姗姗， 徐晓涵， 吴紫阳， 翟所迪， 温剑， 程吟楚 - 药物不良反应杂志, 2022 - cadrj.com
… lung disease (ILD) in patients with non‑small cell lung cancer (… , including 6 about gefitinib,
5 about erlotinib, 2 about icotinib… pemetrexed maintenance therapy for patients with advanced …
5 about erlotinib, 2 about icotinib… pemetrexed maintenance therapy for patients with advanced …
[HTML][HTML] EGFR 突变与非小细胞肺癌放射治疗进展
钟幸， 王瑾 - Chinese Journal of Lung Cancer, 2013 - ncbi.nlm.nih.gov
… 表皮生长因子受体（epidermal growth factor receptor, EGFR）突变是晚期非小细胞肺癌（non-small
cell lung cancer, NSCLC）使用酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）治疗有效…
cell lung cancer, NSCLC）使用酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）治疗有效…
[HTML][HTML] EGFR 基因状态与晚期非小细胞肺癌患者一线化疗疗效的关系
秦娜， 张权， 王敬慧， 张卉， 顾艳斐… - … Journal of Lung …, 2015 - ncbi.nlm.nih.gov
… 本研究旨在探讨对晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）患者一线化疗
疗效… to first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). …
疗效… to first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). …
[HTML][HTML] EGFR 野生型晚期非小细胞肺癌的治疗进展
马峰， 史晓宇， 孟玮， 张敬， 赵丽霞… - … Journal of Lung …, 2014 - ncbi.nlm.nih.gov
… The discovery and development of epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) have had a major impact in the treatment of non small cell lung cancer (NSCLC)…
inhibitor (EGFR-TKI) have had a major impact in the treatment of non small cell lung cancer (NSCLC)…
[HTML][HTML] 132 例晚期非小细胞肺癌胸腔积液EGFR 基因突变检测结果及其临床意义： 一项来自单中心的回顾性研究
鲁涛， 李强， 李岚， 杨凯珍， 周丹菲， 高洁… - … Journal of Lung …, 2020 - ncbi.nlm.nih.gov
… , Treatment, Quality control standards 对于晚期非小细胞肺癌（non-small cell lung cancer, …
Chinese expert group on EGFR gene mutation detection in patients with non-small cell lung …
Chinese expert group on EGFR gene mutation detection in patients with non-small cell lung …
[PDF][PDF] 晚期非小细胞肺癌维持治疗的研究进展
姜怡， 刘苓霜 - 中国中西医结合杂志, 2010 - cjim.cn
… 根据美国Surveillance Epidemiology and End Resuits(SEER)统计,肺癌患者5年生存率美国
为15%, 欧洲为10%,发展中国家为8.9%旧’.非小细胞肺癌 (non-small cell lung cancer,NSCLC)占…
为15%, 欧洲为10%,发展中国家为8.9%旧’.非小细胞肺癌 (non-small cell lung cancer,NSCLC)占…
EGFR-TKI 治疗肺腺癌的疗效与血清肿瘤标志物的相关性
潘金兵， 侯宇虹， 钱皓瑜 - 肿瘤防治研究, 2012 - zlfzyj.com
… to gefitinib in advanced non-small cell lung cancer[J].Eur J … responsiveness of non-small-cell
lung cancer to gefitinib[J].N … shedding in ovarian cancer cellsby erlotinib or cetuximab[J].…
lung cancer to gefitinib[J].N … shedding in ovarian cancer cellsby erlotinib or cetuximab[J].…
[PDF][PDF] 血管内皮生长因子和表皮生长因子信号通路的联合抑制在非小细胞肺癌治疗中的应用
南娟， 刘谦， 丁燕， 张占雀， 周清华 - 中国肺癌杂志, 2009 - core.ac.uk
… EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, …
erlotinib (tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung …
erlotinib (tarceva) compared with erlotinib alone for treatment of advanced non-small cell lung …